Moderna (NASDAQ:MRNA) Given “Market Perform” Rating at William Blair

William Blair reaffirmed their market perform rating on shares of Moderna (NASDAQ:MRNA) in a research note published on Thursday morning,RTT News reports.

Several other equities research analysts have also issued reports on MRNA. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Leerink Partners reduced their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. UBS Group decreased their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Evercore ISI set a $50.00 price target on Moderna in a research report on Friday, February 14th. Finally, Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $58.70.

Moderna Trading Down 1.9 %

NASDAQ MRNA opened at $24.72 on Thursday. The company has a market cap of $9.56 billion, a P/E ratio of -2.66 and a beta of 2.23. Moderna has a 12-month low of $23.15 and a 12-month high of $170.47. The company has a fifty day simple moving average of $30.96 and a 200 day simple moving average of $40.08.

Institutional Investors Weigh In On Moderna

Institutional investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. raised its stake in shares of Moderna by 16.1% during the 1st quarter. QRG Capital Management Inc. now owns 8,274 shares of the company’s stock valued at $235,000 after buying an additional 1,150 shares during the last quarter. BDF Gestion acquired a new position in Moderna during the first quarter worth about $783,000. Janney Montgomery Scott LLC grew its position in shares of Moderna by 37.1% in the first quarter. Janney Montgomery Scott LLC now owns 13,825 shares of the company’s stock valued at $392,000 after purchasing an additional 3,744 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Moderna by 17.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 30,693 shares of the company’s stock valued at $870,000 after acquiring an additional 4,556 shares during the last quarter. Finally, Tobam raised its stake in Moderna by 75.2% during the first quarter. Tobam now owns 44,753 shares of the company’s stock worth $1,269,000 after purchasing an additional 19,208 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.